Core Insights - Gossamer Bio, Inc. (NASDAQ:GOSS) is currently highlighted as one of the most active penny stocks to consider for investment [1] - As of March 16, 2026, 44% of analysts maintain a "Buy" rating for Gossamer Bio, with a consensus price target of $1.00, indicating an upside potential of 117.39% [2] - Recent revisions in forecasts for Gossamer Bio's primary therapy, seralutinib, are attributed to an uncertain regulatory environment [2] Analyst Ratings and Price Targets - H.C. Wainwright & Co. has maintained a "Buy" rating but reduced its price target from $10 to $5, citing a lowered probability of success for seralutinib in pulmonary arterial hypertension (PAH) from 70% to 50% [3] - Oppenheimer & Co. reiterated its "Outperform" rating while lowering its price target from $12 to $3, noting that upcoming FDA interactions and data could mitigate risks associated with seralutinib's approval pathway [4] Company Overview - Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immunology, inflammation, and oncology, with notable projects including GB001 for eosinophilic asthma [5]